Dr Sandip Patel to Speak on Biomarkers for Cancer Immunotherapy: Beyond PD-L1
Summary
The number of technologies now available to better help patients is truly amazing.” Speaking about his work, he said, "I am currently an assistant professor at UCSD Moores Cancer Center focusing on immunotherapeutic biomarker development and early phase clinical trials with combinatorial immunotherapy." When asked about the latest challenges in the biomarker domain Dr Patel told, “Multiple disparate PD-L1 IHC assays with varying cut-offs which are companion diagnostics to a variety of different agents.At the conference experts from pharma, bio - pharma companies and research institutes will be gathering to discuss emerging pathways and breakthroughs in biomarker discovery and successful validation in consort with the regulatory guidelines and evolving cost-effective technologies that can help increase success rates in novel biomarker discovery and approvals for clinical utility.Speaking at the conference are organizations such as Roche, Pfizer, National Biomarker Development Alliance, Novartis Pharmaceuticals Corporation, Eisai, NCI/NIH, Bayer HealthCare, Harvard Medical School, The Wistar Institute, Merck Serono, Janssen Research & Development, FDA | CDRH and Astrazeneca.The number of technologies now available to better help patients is truly amazing.”Speaking about his work, he said, "I am currently an assistant professor at UCSD Moores Cancer Center focusing on immunotherapeutic biomarker development and early phase clinical trials with combinatorial immunotherapy."When asked about the latest challenges in the biomarker domain Dr Patel told, “Multiple disparate PD-L1 IHC assays with varying cut-offs which are companion diagnostics to a variety of different agents.